Kayne Anderson Rudnick Investment Management LLC increased its position in shares of Fresenius Medical Care (NYSE:FMS) by 6.3% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 63,000 shares of the company’s stock after buying an additional 3,740 shares during the quarter. Kayne Anderson Rudnick Investment Management LLC’s holdings in Fresenius Medical Care were worth $3,218,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in the company. CIBC Asset Management Inc raised its position in Fresenius Medical Care by 11.7% in the first quarter. CIBC Asset Management Inc now owns 9,390 shares of the company’s stock valued at $480,000 after purchasing an additional 980 shares during the period. Comerica Bank raised its position in Fresenius Medical Care by 2.4% in the fourth quarter. Comerica Bank now owns 48,984 shares of the company’s stock valued at $2,769,000 after purchasing an additional 1,136 shares during the period. Atwood & Palmer Inc. raised its position in Fresenius Medical Care by 111.1% in the first quarter. Atwood & Palmer Inc. now owns 2,204 shares of the company’s stock valued at $113,000 after purchasing an additional 1,160 shares during the period. D.A. Davidson & CO. raised its position in Fresenius Medical Care by 7.0% in the fourth quarter. D.A. Davidson & CO. now owns 18,039 shares of the company’s stock valued at $948,000 after purchasing an additional 1,185 shares during the period. Finally, ETRADE Capital Management LLC raised its position in Fresenius Medical Care by 14.7% in the first quarter. ETRADE Capital Management LLC now owns 10,127 shares of the company’s stock valued at $517,000 after purchasing an additional 1,298 shares during the period. 2.48% of the stock is currently owned by hedge funds and other institutional investors.
A number of analysts have issued reports on the company. Royal Bank of Canada reissued a “neutral” rating on shares of Fresenius Medical Care in a research report on Thursday, May 3rd. DZ Bank reissued a “buy” rating on shares of Fresenius Medical Care in a research report on Thursday, April 5th. Zacks Investment Research raised Fresenius Medical Care from a “hold” rating to a “buy” rating and set a $58.00 target price on the stock in a research report on Thursday, March 8th. Finally, Deutsche Bank raised Fresenius Medical Care from a “hold” rating to a “buy” rating in a research report on Tuesday, April 24th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the stock. Fresenius Medical Care currently has a consensus rating of “Hold” and a consensus price target of $54.67.
Shares of Fresenius Medical Care opened at $50.46 on Friday, according to MarketBeat. The company has a market capitalization of $30.86 billion, a price-to-earnings ratio of 22.83, a PEG ratio of 2.73 and a beta of 0.62. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.01 and a current ratio of 1.26. Fresenius Medical Care has a 52-week low of $44.88 and a 52-week high of $57.94.
Fresenius Medical Care (NYSE:FMS) last posted its quarterly earnings results on Thursday, May 3rd. The company reported $0.49 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.70 by ($0.21). The business had revenue of $3.98 billion during the quarter, compared to analyst estimates of $4.07 billion. Fresenius Medical Care had a return on equity of 11.09% and a net margin of 7.29%. The business’s revenue was down 12.6% on a year-over-year basis. During the same quarter last year, the firm earned $1.01 EPS. analysts predict that Fresenius Medical Care will post 2.63 earnings per share for the current fiscal year.
The firm also recently declared an annual dividend, which will be paid on Monday, June 4th. Shareholders of record on Tuesday, May 22nd will be paid a $0.436 dividend. The ex-dividend date of this dividend is Monday, May 21st. This represents a dividend yield of 0.86%. Fresenius Medical Care’s dividend payout ratio (DPR) is 19.46%.
Fresenius Medical Care Company Profile
Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the U.S.
Receive News & Ratings for Fresenius Medical Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care and related companies with MarketBeat.com's FREE daily email newsletter.